Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00366106 · OUTCOME

Time to Progression (TTP)

Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma · Source last updated 2012-04-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Months
Interval / dispersion
Standard Deviation
Time frame
TTP was measured from day 1 of treatment until time of progression, assessed up to 40 months

Groups in this outcome

Treatment Group

All subjects received bortezomib 1.3mg/m\^2 on Days 1, 4, 15, and 18 every 28 days and dexamethasone 20mg daily on Days 1, 2, 4, 5, 15, 16, 18, and 19 every 28 days. Following US FDA approval of doxorubicin HCl liposome injection in combination with bortezomib in May 2007, the study was amended to allow combination treatment with both bortezomib and doxorubicin HCl liposome injection 30 mg/m\^2 on Day 4 every 28 days with dexamethasone. The target goal was 8 cycles of treatment.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment Group32

Reported measurements

Source class 1
Values in Months · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Treatment Group23.073.20Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        3.20
        value
        23.07
denoms
  1. counts
    1. group Id
      OG000
      value
      32
    units
    Participants
dispersion Type
Standard Deviation
groups
  1. description
    All subjects received bortezomib 1.3mg/m\^2 on Days 1, 4, 15, and 18 every 28 days and dexamethasone 20mg daily on Days 1, 2, 4, 5, 15, 16, 18, and 19 every 28 days. Following US FDA approval of doxorubicin HCl liposome injection in combination with bortezomib in May 2007, the study was amended to allow combination treatment with both bortezomib and doxorubicin HCl liposome injection 30 mg/m\^2 on Day 4 every 28 days with dexamethasone. The target goal was 8 cycles of treatment.
    id
    OG000
    title
    Treatment Group
param Type
MEAN
reporting Status
POSTED
time Frame
TTP was measured from day 1 of treatment until time of progression, assessed up to 40 months
title
Time to Progression (TTP)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice